VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma

Leukemia

Volumn 22, Issue 7, 2008, Pages 1419-1427

  Pineda Roman, M ^a   Zangari, M ^a   van Rhee, F ^a   Anaissie, E ^a   Szymonifka, J ^b   Hoering, A ^b   Petty, N ^a   Crowley, J ^b   Shaughnessy, J ^a   Epstein, J ^a   Barlogie, B ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; THALIDOMIDE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER REGRESSION; CHROMOSOME ABERRATION; CLINICAL TRIAL; COHORT ANALYSIS; CONFUSION; DEPRESSION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HYPOKALEMIA; HYPOPHOSPHATEMIA; KIDNEY FAILURE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MOOD DISORDER; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; SENSORY NEUROPATHY; SEPSIS; SUBDURAL HEMATOMA; THROMBOCYTOPENIA; TREATMENT DURATION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; THALIDOMIDE;

EID: 47549115250     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.99     Document Type: Article

References (42)

1. Hideshima T, Chauhan D, Richardson P, Anderson KC. Identification and validation of novel therapeutic targets for multiple myeloma. J Clin Oncol 2005; 23: 6345-6350.
2. Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: 3058-3065.
3. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
4. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
5. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
6. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492-494.
7. Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ et al Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208: 1680-1685.
8. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431-436.
9. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16-19.
10. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996; 31: 213-221.
11. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ et al Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999; 163: 380-386.
12. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999; 59: 728-733.
13. Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R et al Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999; 93: 3064-3073.
14. Zangari M, Barlogie B, Jacobson J, Rasmussen E, Burns M, Kordsmeier B et al. VTD regimen comprising velcade (V) + thalidomide (T) and added DEX (D) for non-responders to V + T effects a 57% PR rate among 56 patients with myeloma (M) relapsing after autologous transplant. Blood 2003; 102: 830 (abstract).
15. Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E et al. Treatment of multiple myeloma. Blood 2004; 103: 20-32.
16. Barlogie B, Alexanian R, Pershouse M, Smallwood L, Smith L. Cytoplasmic immunoglobulin content in multiple myeloma. J Clin Invest 1985; 76: 765-769.
17. Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995; 82: 41-49.
18. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002; 99: 1745-1757.
19. Shaughnessy Jr JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109: 2276-2284.
20. Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy Jr JD et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 2007; 25: 1121-1128.
21. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123.
22. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. Am Stat Association 1958; 53: 457-481.
23. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 695-706.
24. Cox DR. Regression tables and life tables. J R Stat Soc 1972; B34: 187-202.
25. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020-2028.
26. Pineda-Roman M, Zangari M, Haessler J, Anaissie E, Tricot G, van Rhee F et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: Comparison with total therapy 2. Br J Haematol 2008; 140: 625-634.
27. Cheng W, Kuehl W, Bergsagel P, Fonseca R. Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature. Leukemia 2007; 22: 459-461.
28. Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007; 109 3177-3188.
29. Zhan F, Barlogie B, Mulligan G, Shaughnessy Jr JD, Bryant B. High-risk myeloma: A gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. Blood 2008; 111: 968-969.
30. Barlogie B, Haessler J, Pineda-Roman M, Zangari M, Anaissie E, van Rhee F et al. Completion of pre-maintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma - an important variable to be considered in clinical trial designs. Cancer 2008; In press.
31. Wang M, Delasalle K, Giralt S, Alexanian R. Rapid control of previously untreated multiple myeloma with bortezomib-thalido-mide-dexamethasone followed by early intensive therapy. Blood 2005; 106: 784 (abstract).
32. van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007; 110: 827-832.
33. Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M et al. Incorporating bortezomib into upfront treatment for multiple myeloma: Early results of total therapy 3. Br J Haematol 2007; 138: 176-185.
34. Richardson P, Jagannath S, Avigan D, Alsina M, Schlossman R, Mazumder A et al. Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): Final results of a multicenter phase 1 trial. Blood 2006; 108: 405 (abstract).
35. Mateos MV, Hernandez JM, Hernandez MT, Gutierrez NC, Palomera L, Fuertes M et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1/2 study. Blood 2006; 108: 2165-2172.
36. Terpos E, Anagnostopoulos A, Kastritis E, Zomas A, Poziopoulo C, Anagnostopoulos N et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT) is an effective treatment for relapsed/refractory myeloma: Results of a phase II clinical trial. Blood 2005; 106: 363 (abstract).
37. Palumbo A, Ambrosini MT, Benevolo G, Pregno P, Pescosta N, Callea V et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 2007; 109: 2767-2772.
38. Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer 2005; 103: 1195-1200.
39. Hollmig K, Stover J, Talamo G, Fassas A, Lee C, Anaissie E. Bortezomib (VelcadeTM) + AdriamycinTM + thalidomide + dexamethasone (VATD) as an effective regimen in patients with refractory or relapsed multiple myeloma (MM). Blood 2004; 104: 2399 (abstract).
40. Barlogie B, Anaissie E, van Rhee F, Pineda-Roman M, Zangari M, Shaughnessy J et al. The Arkansas approach to therapy of patients with multiple myeloma. Best Pract Res 2007; 20: 761-781.
41. Murakawa Y, Sonoda E, Barber LJ, Zeng W, Yokomori K, Kimura H et al. Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells. Cancer Res 2007; 67: 8536-8543.
42. Pineda-Roman M, Fox M, Hollmig K, Anaissie E, van Rhee F, Tricot G et al. Retrospective analysis of fractionated high-dose melphalan (F-MEL) and bortezomib-thalidomide-dexamethasone (VTD) with autotransplant (AT) support for advanced and refractory multiple myeloma (AR-MM). Blood 2006; 108: 3102 (abstract).